In this issue of Blood, Wang et al reveal that ligation of Ly6G on murine neutrophils inhibits neutrophil recruitment, providing the first evidence of a function for this molecule.

Since the presentation of trials such as the Intergroup N9741 study (National Cancer Institute of Canada CO.15) and the MOSAIC (Multicenter International Study of Oxaliplatin/5-FU–LV in the Adjuvant Treatment of Colon Cancer) trial at the 2003 American Society of Clinical Oncology meeting, oncologists have broadly accepted that oxaliplatin is part of the standard management of colorectal cancer...